A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours

被引：0

作者：

de Bono, J. S. ^{[1
]}

Lord, S. ^{[2
]}

Yap, C. ^{[3
]}

Rowinsky, E. K. ^{[4
]}

Gandhi, N. A. ^{[4
]}

Thakkar, D. ^{[5
]}

Ingram, P. J. ^{[5
]}

Padmanabhan, N. ^{[6
]}

Chandran, K. ^{[7
,8
]}

Paschalis, A. ^{[9
]}

McGuigan, L. ^{[10
]}

Neal, P. ^{[10
]}

Paisley, D. ^{[10
]}

Walter, H. S. ^{[10
]}

Kelly, F. ^{[10
]}

Craigan, J. ^{[10
]}

Westwood, N. B. ^{[10
]}

Halbert, G. ^{[10
]}

Boyd-Kirkup, J. D. ^{[11
]}

Halford, S. E. R. ^{[10
]}

机构：

[1] ICR Inst Canc Res, London, England

[2] Univ Oxford, Oncol, Oxford, England

[3] ICR Inst Canc Res North Site, Clin Trials Biostat Dept, Sutton, England

[4] Hummingbird Biosci, Dis Area Strategy, Houston, TX USA

[5] Hummingbird Biosci Pte Ltd, Pharmacol Dept, Temasek Lifesci Labs, Singapore, Singapore

[6] Hummingbird Biosci Pte Ltd, Pharmacol, Temasek Lifesci Labs, Singapore, Singapore

[7] Inst Canc Res, Med Oncol, Sutton, England

[8] Royal Marsden Hosp, Sutton, England

[9] ICR Inst Canc Res, Clin Studies, London, England

[10] CRUK Canc Res UK, Ctr Drug Dev, London, England

[11] Hummingbird Biosci Pte Ltd, Res, Temasek Lifesci Labs, Singapore, Singapore

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.621

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

493TiP

引用

页码：S767 / S767

页数：1

共 50 条

[1] A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER3 antibody) in patients with advanced HER3 positive solid tumours
de Bono, J. S.
Lord, S.
Yap, C.
Miranda, S.
Veal, G. J.
Chandran, K.
Paschalis, A.
Peron, C.
Rekowski, J.
Gurel, B.
Paisley, D.
McGuigan, L.
Ingram, P. J.
Kwek, K. Y.
Halbert, G.
Westwood, N. B.
Griffin, A. E.
Kostaras, L.
Boyd-Kirkup, J. D.
Walter, H. S.
ANNALS OF ONCOLOGY, 2023, 34 : S479 - S480
[2] Pharmacokinetics of HMBD-001, a human monoclonal antibody targeting HER3, a CRUK first-in-human phase I trial in patients with advanced solid tumours
Idowu, O.
Craigen, J.
Svetlik, S.
Veal, J.
Jamieson, D.
ANNALS OF ONCOLOGY, 2023, 34 : S480 - S480
[3] First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
Meulendijks, Didier
Jacob, Wolfgang
Martinez-Garcia, Maria
Taus, Alvaro
Lolkema, Martijn P.
Voest, Emile E.
Langenberg, Marlies H. G.
Fleitas Kanonnikoff, Tania
Cervantes, Andres
De Jonge, Maja J.
Sleijfer, Stefan
Soerensen, Morten Mau
Thomas, Marlene
Ceppi, Maurizio
Meneses-Lorente, Georgina
James, Ian
Adessi, Celine
Michielin, Francesca
Abiraj, Keelara
Bossenmaier, Birgit
Schellens, Jan H. M.
Weisser, Martin
Lassen, Ulrik N.
CLINICAL CANCER RESEARCH, 2016, 22 (04) : 877 - 885
[4] Trial in Progress: A Phase Ib Study of HMBD-001, An Anti-HER3 Antibody, in Advanced Squamous NonSmall Cell Lung Cancer
Pavlakis, N.
Kichenadasse, G.
Richardson, G.
Bowyer, S.
Andelkovic, V.
Ganju, V.
Tan, A.
Samol, J.
Thomas, D.
Fernandez, A. Mas
Paszkiewicz, K.
Ingram, P.
Boyd-Kirkup, J.
Kwek, K. Y.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S350 - S350
[5] Development and validation of an ELISA method for quantification of the anti-HER3 antibody HMBD-001 in human serum
Idowu, Oladipo S.
Craigen, Jenny L.
Veal, Gareth J.
Jamieson, David
BIOANALYSIS, 2022, 14 (18) : 1241 - 1249
[6] A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Pavlakis, N.
Millward, M.
Richardson, G.
Andelkovic, V.
Kichenadasse, G.
Thomas, D. M.
Fernandez, A. Mas
Thakkar, D.
Arbabzade, T.
Goey, C. H.
Seet, Q.
Toy, W.
Paszkiewicz, K.
Ingram, P. J.
Boyd-Kirkup, J. D.
Kwek, K. Y.
ANNALS OF ONCOLOGY, 2023, 34 : S1501 - S1501
[7] First-in-human, phase I dose escalation and expansion study of anti-HER2 ADC MRG002 in patients with HER2 positive solid tumors
Guo, Y.
Xue, J.
Peng, W.
Xue, L.
Ge, X.
Zhao, W.
Tang, W.
Nian, W.
Li, Q.
Zhang, S.
Sun, J.
Li, M.
Hausheer, F.
Hu, C.
Li, J.
ANNALS OF ONCOLOGY, 2021, 32 : S480 - S481
[8] A first-in-human phase I/Ib dose-escalation clinical trial of the autophagy inducer ABTL0812 in patients with advanced solid tumours
Vidal, Laura
Victoria, Ivan
Gaba, Lydia
Martin, Marta Gil
Brunet, Merce
Colom, Helena
Cortal, Marc
Gomez-Ferreria, Mariana
Yeste-Velasco, Marc
Perez, Antonio
Rodon, Jordi
Sohal, Davendra P. S.
Lizcano, Jose Miguel
Domenech, Carles
Alfon, Jose
Gascon, Pere
EUROPEAN JOURNAL OF CANCER, 2021, 146 : 87 - 94
[9] A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours
Krauss, J.
Eigentler, T.
Schreiber, J.
Weishaupt, C.
Terheyden, P.
Heinzerling, L.
Mohr, P.
Weide, B.
Ochsenreither, S.
Gutzmer, R.
Becker, J. C.
Kiecker, F.
Funkner, F.
Heidenreich, R.
Kays, S-K.
Klinkhardt, U.
Gnad-Vogt, U. S.
Scheel, B.
Schoenborn-Kellenberger, O.
Seibel, T.
ANNALS OF ONCOLOGY, 2019, 30 : 191 - +
[10] Safety, tolerability, and pharmacokinetics of an anti-LAG-3 antibody SHR-1802 in patients with advanced solid tumors: a phase I dose-escalation and dose-expansion study
Deng, Ting
Liu, Zhigang
Han, Zhengquan
Zhou, Huan
Liu, Rui
Li, Yijing
Li, Shaorong
Xiu, Peng
Wang, Shuni
Zhang, Yiping
Ba, Yi
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15

← 1 2 3 4 5 →